title: [Loco-regional thrombolysis in deep venous thrombosis].
abstract: Anticoagulation, by means of heparin and warfarin is, till now, the most common treatment in deep venous thrombosis. Although thrombolytic agents have been available for over 10 years, their use remains quite low, ranging from 15 to 20% of deep venous thromboses. This is due to the relatively high incidence of contraindications as well as to the fact that the potential advantages versus heparin are diminished by the increased bleeding risk and by the potential risk of pulmonary embolism (migration of partially lysed thrombi). Following the example of the "triple armed therapy" proposed by Rosenthal for the treatment of pulmonary embolism, we will evaluate if loco-regional thrombolysis, with the catheter wedged against the thrombus, associated with a temporary vena cava interruption by means of an intraluminal filter, can achieve a better lysis of the thrombus without pulmonary embolism. In our Unit 18 patients affected by proximal deep venous thrombosis were submitted to thrombolytic therapy, 6 to systemic treatment, 3 to local treatment and the last 9 to loco-regional thrombolysis, using recombinant tissue-type Plasminogen Activator. We obtained 10 complete lyses, 1 with systemic and 9 with loco-regional treatment. There were no major complications. Thus, we think that venous loco-regional thrombolysis with rt-PA at lower doses, associated with temporary caval interruption, can probably achieve a better lysis than systemic treatment without risk of pulmonary embolism and with a very low haemorrhagic risk, as in arterial loco-regional thrombolysis. Furthermore, loco-regional thrombolysis, by means of a faster thrombus dissolution, could better prevent post-phlebitic syndrome.
authors.affiliation: Unité de chirurgie vasculaire et angéiologie, Hôpital Régional du Val-d' Aoste, Italie.
authors.forename: D
authors.initials: D
authors.lastname: Palombo
authors.forename: C
authors.initials: C
authors.lastname: Porta
authors.forename: P
authors.initials: P
authors.lastname: Brustia
authors.forename: F
authors.initials: F
authors.lastname: Peinetti
authors.forename: M
authors.initials: M
authors.lastname: Udini
authors.forename: A
authors.initials: A
authors.lastname: Antico
authors.forename: M
authors.initials: M
authors.lastname: Maione
authors.forename: T
authors.initials: T
authors.lastname: Meloni
authors.forename: P
authors.initials: P
authors.lastname: Carbonato
mesh_terms: D002406:Catheterization, Peripheral; D004617:Embolism / Q000517:prevention & control; D005268:Femoral Vein; D006470:Hemorrhage / Q000517:prevention & control; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007084:Iliac Vein; D010690:Phlebography; D012008:Recurrence; D015912:Thrombolytic Therapy / Q000379:methods*; D013924:Thrombophlebitis / Q000000981:diagnostic imaging / Q000188:drug therapy*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use*; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use; D016306:Vena Cava Filters
chemical_list: D006493:Heparin; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator
vernacular_title: La thrombolyse loco-régionale dans la thrombose veineuse profonde.